Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Calcium hydroxylapatite + lidocaine is an injectable soft tissue filler formulation combining synthetic calcium hydroxylapatite (CaHA) microspheres suspended in a gel carrier with 0.3% lidocaine. The lidocaine component is included to reduce pain and discomfort during the injection procedure. The product is primarily indicated for subdermal implantation to correct moderate-to-severe facial wrinkles and folds (such as nasolabial folds). The CaHA microspheres provide immediate volume correction and stimulate endogenous collagen production (neocollagenesis), resulting in long-lasting results for facial rejuvenation and volume restoration. The addition of lidocaine does not alter the performance, safety, or aesthetic efficacy of the filler, and is associated with significantly reduced pain ratings during and after injection[2][4][9][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on calcium hydroxylapatite + lidocaine.